SCHEMBL3408934

SCHEMBL3408934

CNc1ccc(F)cc1I

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.38
HTT P42858 1/20 0.35
HDAC1 Q13547 3/20 0.34
CCNE2 O96020 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
POLB P06746 2/20 0.33
MAPT P10636 2/20 0.33
IKBKB O14920 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
ALOX12 P18054 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PKM P14618 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TRPA1 O75762 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5510041 0.78 ALDH1A1 (0.39) HTTHDAC1CCNE2CCNE1CDK2
SCHEMBL24006853 0.77 HDAC1 (0.38) HTTHDAC1POLBMAPTMEN1
SCHEMBL10003657 0.77 CYP1A2 (0.34) HTTHDAC1POLBMAPTPKM
SCHEMBL31260970 0.77 HDAC1 (0.38) HTTHDAC1POLBMAPTMEN1
SCHEMBL306848 0.76 HTT (0.50) HTTPOLBMAPTMEN1ALDH1A1
SCHEMBL21668012 0.76 APP (0.40) APPPOLBMAPTALDH1A1TDP1
Hydrochloric Acid SCHEMBL28982101 0.76 HDAC1 (0.37) HTTHDAC1POLBMAPTMEN1
SCHEMBL19122138 0.74 APP (0.39) APPHTTMEN1ALDH1A1KMT2A
SCHEMBL854924 0.74 ALDH1A1 (0.44) HTTCCNE2CCNE1CDK2POLB
SCHEMBL3408837 0.74 CA1 (0.57) HTTHDAC1CDK2POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2254864-B1 SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2014-05-14 EP disclosed
CN-101360752-B Hiv integrase inhibitors BRISTOL MYERS SQUIBB CO 2012-09-05 CN disclosed
CN-102015640-A Substituted 4-aminocyclohexane derivatives for the treatment of pain GRUENENTHAL GMBH 2011-04-13 CN disclosed
EP-2254864-A1 SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN Grünenthal GmbH (DE) 2010-12-01 EP disclosed
WO-2010097334-A1 DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed
WO-2009106307-A1 SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF PAIN Grünenthal GmbH (DE) 2009-09-03 WO disclosed
US-20090215725-A1 Substituted 4-aminocyclohexane derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US disclosed
CN-101360752-A HIV integrase inhibitors BRISTOL MYERS SQUIBB CO (US) 2009-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215725-A1 Substituted 4-aminocyclohexane derivatives OPRL1, OPRD1, OPRK1 APP 2019/4885HTT 1884/4885HDAC1 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.